In conclusion, our study suggested that ICIs combined with ChT improved clinical outcomes compared with Beva combined with ChT as the first‐line therapy in adenocarcinoma patients without driver gene alterations. This evidence concerns the gene SLC5A7 and adenocarcinoma.